Go offline with the Player FM app!
Mitigating Muscle Loss from GLP-1 Agonists, with Dr. Anurag Singh
Manage episode 414607535 series 1149419
Even as we prioritize natural interventions in functional medicine, GLP-1 agonist drugs such as Wegovy and Ozempic offer sometimes life-changing support for those who have long struggled with resistant overweight/obesity and high blood sugar. However, there are side effects, including the risk of substantial muscle loss and sagging, aged skin ("Ozempic face" as it's indelicately known). It's a concern that hits home for me, considering the pivotal role we know that muscle plays in overall health and longevity.
In this New Frontiers podcast episode I welcome back Dr. Anurag Singh to unravel the complexities of these issues. We explore the interplay between metabolic health and muscle preservation, touching on everything from the mechanisms of GLP-1 agonists and their long-term effects on aging and sarcopenia, to the promising potential of dietary and lifestyle interventions to counteract negative effects. We consider the potential for one of my all-time fave postbiotic epinutrients - Urolithin A - to assist by supporting mitochondrial health and preserving/enhancing muscle quality. This timely conversation is one you won't want to miss. Tune in and please leave us a review wherever you listen to New Frontiers. – DrKF
Check out our show notes https://www.drkarafitzgerald.com/fxmed-podcast/
Guest information
Anurag Singh, MD, PhD
Chief Medical Officer at Timeline
Thank you to our sponsor
- Timeline
- Mitopure
- Research from Timeline
- care@timeline.com
Timeline Discount for New Frontiers Listeners
Timeline is offering DrKFs readers a 10% discount on Timeline products. Head over to Timeline and use the code KARA10 at checkout.
Show Notes
- Study: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://tinyurl.com/y3c2ypkw
176 episodes
Mitigating Muscle Loss from GLP-1 Agonists, with Dr. Anurag Singh
Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics
Manage episode 414607535 series 1149419
Even as we prioritize natural interventions in functional medicine, GLP-1 agonist drugs such as Wegovy and Ozempic offer sometimes life-changing support for those who have long struggled with resistant overweight/obesity and high blood sugar. However, there are side effects, including the risk of substantial muscle loss and sagging, aged skin ("Ozempic face" as it's indelicately known). It's a concern that hits home for me, considering the pivotal role we know that muscle plays in overall health and longevity.
In this New Frontiers podcast episode I welcome back Dr. Anurag Singh to unravel the complexities of these issues. We explore the interplay between metabolic health and muscle preservation, touching on everything from the mechanisms of GLP-1 agonists and their long-term effects on aging and sarcopenia, to the promising potential of dietary and lifestyle interventions to counteract negative effects. We consider the potential for one of my all-time fave postbiotic epinutrients - Urolithin A - to assist by supporting mitochondrial health and preserving/enhancing muscle quality. This timely conversation is one you won't want to miss. Tune in and please leave us a review wherever you listen to New Frontiers. – DrKF
Check out our show notes https://www.drkarafitzgerald.com/fxmed-podcast/
Guest information
Anurag Singh, MD, PhD
Chief Medical Officer at Timeline
Thank you to our sponsor
- Timeline
- Mitopure
- Research from Timeline
- care@timeline.com
Timeline Discount for New Frontiers Listeners
Timeline is offering DrKFs readers a 10% discount on Timeline products. Head over to Timeline and use the code KARA10 at checkout.
Show Notes
- Study: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://tinyurl.com/y3c2ypkw
176 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.